# Serum PTX3 Levels Correlate with Fibrous Cap Discontinuity and Focal Inflammation in Carotid Vulnerable Plaque: A High-Resolution Magnetic Resonance Vessel Wall Imaging Study

**Authors:** Tingting Li, Lu Li, Qingyuan Wang, Yumeng Sun, Jianxiu Lian, Wei Yu

PMC · DOI: 10.3390/jcm15041452 · 2026-02-12

## TL;DR

This study shows that higher levels of a blood protein called PTX3 are linked to unstable carotid artery plaques, which can lead to strokes.

## Contribution

The study demonstrates that serum PTX3 is a novel biomarker for identifying vulnerable carotid plaque features using high-resolution MRI.

## Key findings

- Serum PTX3 levels increase with the severity of carotid plaque vulnerability.
- PTX3 independently predicts fibrous cap discontinuity and focal inflammation in carotid plaques.
- PTX3 levels correlate with the number of vulnerable plaque features detected via MRI.

## Abstract

Background: Pentraxin 3 (PTX3) is a well-established inflammatory biomarker with significant implications in the pathogenesis and prognostic assessment of cardiovascular diseases. This study aimed to investigate the potential value of serum PTX3 as a circulating biomarker when combined with the high-resolution magnetic resonance vessel wall imaging (HR-VWI) for identifying carotid vulnerable plaque (CVP) and its specific vulnerable features. Methods: This prospective cross-sectional study enrolled 86 patients with carotid atherosclerosis who underwent HR-VWI. Patients were classified into CVP and non-carotid vulnerable plaque (NCVP) groups, and CVP was divided into unilateral carotid vulnerable plaque (UCVP) and bilateral carotid vulnerable plaque (BCVP). CVP was defined as meeting ≥ 1 major criteria: lipid-rich necrotic core (LRNC) maximum area percentage > 40% combined with thin fibrous cap (FC), intraplaque hemorrhage (IPH), FC discontinuity, and focal inflammation. Multivariate logistic regression analysis identified factors influencing CVP and the formation of specific vulnerable features. Results: Serum PTX3 levels progressively increased across the NCVP, UCVP, and BCVP groups (median 638.23, 858.52, 1113.62 pg/mL; p < 0.001). PTX3 independently predicted the presence of CVP (OR = 2.88; 95% CI: 1.16–8.91; p = 0.039) and specific vulnerable features, including FC discontinuity (OR = 2.47; 95% CI: 1.32–4.63; p = 0.005) and focal inflammation (OR = 2.25; 95% CI: 1.18–4.32; p = 0.014) with high diagnostic performance for these conditions. PTX3 levels exhibited a moderate positive correlation with the number of vulnerable features (r = 0.610, p < 0.01). Conclusions: Elevated serum PTX3 levels were significantly associated with HR-VWI-defined carotid plaque vulnerability and its severity, serving as a reliable circulating biomarker for identifying FC discontinuity and focal inflammation.

## Linked entities

- **Genes:** PTX3 (pentraxin 3) [NCBI Gene 5806]

## Full-text entities

- **Genes:** TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}, MMP9 (matrix metallopeptidase 9) [NCBI Gene 4318] {aka CLG4B, GELB, MANDP2, MMP-9}, NPPB (natriuretic peptide B) [NCBI Gene 4879] {aka BNP, Iso-ANP}, C1QA (complement C1q A chain) [NCBI Gene 712] {aka C1QD1}, CD163 (CD163 molecule) [NCBI Gene 9332] {aka M130, MM130, SCARI1}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, SELP (selectin P) [NCBI Gene 6403] {aka CD62, CD62P, GMP140, GRMP, LECAM3, PADGEM}, FGF2 (fibroblast growth factor 2) [NCBI Gene 2247] {aka BFGF, FGF-2, FGFB, HBGF-2}, VCAM1 (vascular cell adhesion molecule 1) [NCBI Gene 7412] {aka CD106, INCAM-100}, MMP1 (matrix metallopeptidase 1) [NCBI Gene 4312] {aka CLG}, SELE (selectin E) [NCBI Gene 6401] {aka CD62E, ELAM, ELAM1, ESEL, LECAM2, selectin-e}, PTX3 (pentraxin 3) [NCBI Gene 5806] {aka TNFAIP5, TSG-14}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}
- **Diseases:** vascular occlusions (MESH:D008641), atherosclerosis (MESH:D050197), acute coronary syndrome (MESH:D054058), dyslipidemia (MESH:D050171), hypertension (MESH:D006973), hematologic disease (MESH:D006402), CVP (MESH:D016893), thrombosis (MESH:D013927), Carotid atherosclerosis (MESH:D002340), hepatic and renal insufficiency (MESH:D048550), restenosis (MESH:D023903), FC (MESH:C579969), ischemic cerebral lesions (MESH:D002539), Inflammation (MESH:D007249), injury to (MESH:D014947), familial hypercholesterolemia (MESH:D006938), vascular injury (MESH:D057772), cerebrovascular disease (MESH:D002561), calcification (MESH:D002114), ischemic stroke (MESH:D002544), diabetes mellitus (MESH:D003920), ischemic (MESH:D002545), infections (MESH:D007239), cardiovascular diseases (MESH:D002318), acute myocardial infarction (MESH:D009203), cardiac involvement (MESH:D006331), coronary artery disease (MESH:D003324), stroke (MESH:D020521), IPH (MESH:D006470), heart failure (MESH:D006333), embolism (MESH:D004617), coronary artery stenosis (MESH:D023921), lacunar infarction (MESH:D059409), necrotic (MESH:D009336), LRNC (MESH:D011017), atherosclerotic plaque (MESH:D058226), stenosis (MESH:D003251)
- **Chemicals:** thyroid-stimulating hormones (MESH:D013972), FC (-), telmisartan (MESH:D000077333), TG (MESH:D014280), Hcy (MESH:D006710), lipid (MESH:D008055), Gd (MESH:D005682), cholesterol (MESH:D002784), nitric oxide (MESH:D009569), alcohol (MESH:D000438)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12942235/full.md

---
Source: https://tomesphere.com/paper/PMC12942235